Logo image of MDXH

MDXHEALTH (MDXH) Stock Fundamental Analysis

USA - NASDAQ:MDXH - BE0974461940 - Common Stock

3.97 USD
-0.15 (-3.64%)
Last: 11/13/2025, 4:30:01 PM
3.9 USD
-0.07 (-1.76%)
After Hours: 11/13/2025, 4:30:01 PM
Fundamental Rating

2

MDXH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. MDXH has a bad profitability rating. Also its financial health evaluation is rather negative. MDXH shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MDXH had negative earnings in the past year.
MDXH had a negative operating cash flow in the past year.
MDXH had negative earnings in each of the past 5 years.
MDXH had a negative operating cash flow in each of the past 5 years.
MDXH Yearly Net Income VS EBIT VS OCF VS FCFMDXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -39.12%, MDXH is in line with its industry, outperforming 59.70% of the companies in the same industry.
Industry RankSector Rank
ROA -39.12%
ROE N/A
ROIC N/A
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
MDXH Yearly ROA, ROE, ROICMDXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

MDXH has a Gross Margin of 63.21%. This is in the better half of the industry: MDXH outperforms 79.66% of its industry peers.
In the last couple of years the Gross Margin of MDXH has grown nicely.
MDXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
MDXH Yearly Profit, Operating, Gross MarginsMDXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDXH has more shares outstanding
MDXH has more shares outstanding than it did 5 years ago.
MDXH has a worse debt/assets ratio than last year.
MDXH Yearly Shares OutstandingMDXH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MDXH Yearly Total Debt VS Total AssetsMDXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

MDXH has an Altman-Z score of -2.69. This is a bad value and indicates that MDXH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.69, MDXH is in line with its industry, outperforming 47.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.69
ROIC/WACCN/A
WACC8.82%
MDXH Yearly LT Debt VS Equity VS FCFMDXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.31 indicates that MDXH should not have too much problems paying its short term obligations.
MDXH has a worse Current ratio (1.31) than 84.18% of its industry peers.
MDXH has a Quick Ratio of 1.22. This is a normal value and indicates that MDXH is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MDXH (1.22) is worse than 85.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.22
MDXH Yearly Current Assets VS Current LiabilitesMDXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

MDXH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.89%, which is quite impressive.
Looking at the last year, MDXH shows a very strong growth in Revenue. The Revenue has grown by 28.29%.
Measured over the past years, MDXH shows a very strong growth in Revenue. The Revenue has been growing by 50.17% on average per year.
EPS 1Y (TTM)57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)28.29%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%17.64%

3.2 Future

Based on estimates for the next years, MDXH will show a very strong growth in Earnings Per Share. The EPS will grow by 25.99% on average per year.
The Revenue is expected to grow by 25.31% on average over the next years. This is a very strong growth
EPS Next Y59.84%
EPS Next 2Y33.9%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year24.31%
Revenue Next 2Y22.75%
Revenue Next 3Y22.89%
Revenue Next 5Y25.31%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MDXH Yearly Revenue VS EstimatesMDXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
MDXH Yearly EPS VS EstimatesMDXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MDXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MDXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH Price Earnings VS Forward Price EarningsMDXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH Per share dataMDXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as MDXH's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.9%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MDXHEALTH

NASDAQ:MDXH (11/13/2025, 4:30:01 PM)

After market: 3.9 -0.07 (-1.76%)

3.97

-0.15 (-3.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)N/A N/A
Inst Owners43.66%
Inst Owner Change0%
Ins Owners8.29%
Ins Owner ChangeN/A
Market Cap108.33M
Revenue(TTM)90.05M
Net Income(TTM)-55.01M
Analysts86.67
Price Target6.63 (67%)
Short Float %0.11%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.94%
Min EPS beat(2)-43.29%
Max EPS beat(2)-18.6%
EPS beat(4)1
Avg EPS beat(4)-19.65%
Min EPS beat(4)-45.24%
Max EPS beat(4)28.51%
EPS beat(8)1
Avg EPS beat(8)-60.89%
EPS beat(12)2
Avg EPS beat(12)-45.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.97%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)-0.88%
Revenue beat(4)2
Avg Revenue beat(4)2.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)6.42%
Revenue beat(8)6
Avg Revenue beat(8)3.72%
Revenue beat(12)10
Avg Revenue beat(12)12.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)17.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.89%
EPS NY rev (1m)3.47%
EPS NY rev (3m)-5.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)1.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS5.37
BVpS-0.03
TBVpS-2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.21%
FCFM N/A
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
F-Score5
Asset Turnover1.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.99%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.22
Altman-Z -2.69
F-Score5
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)61.59%
Cap/Depr(5y)46.12%
Cap/Sales(3y)6.93%
Cap/Sales(5y)5.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y59.84%
EPS Next 2Y33.9%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)28.29%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%17.64%
Revenue Next Year24.31%
Revenue Next 2Y22.75%
Revenue Next 3Y22.89%
Revenue Next 5Y25.31%
EBIT growth 1Y22.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.26%
EBIT Next 3Y46.4%
EBIT Next 5Y37.89%
FCF growth 1Y59.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.11%
OCF growth 3YN/A
OCF growth 5YN/A

MDXHEALTH / MDXH FAQ

Can you provide the ChartMill fundamental rating for MDXHEALTH?

ChartMill assigns a fundamental rating of 2 / 10 to MDXH.


What is the valuation status for MDXH stock?

ChartMill assigns a valuation rating of 1 / 10 to MDXHEALTH (MDXH). This can be considered as Overvalued.


Can you provide the profitability details for MDXHEALTH?

MDXHEALTH (MDXH) has a profitability rating of 1 / 10.


What is the financial health of MDXHEALTH (MDXH) stock?

The financial health rating of MDXHEALTH (MDXH) is 1 / 10.